Brief: CVRx Receives FDA Approval For Expanded Labeling Of Barostim
26/12/2023 13:21
Dec 26 (Reuters) - CVRx Inc CVRX.O :
* CVRX RECEIVES FDA APPROVAL FOR EXPANDED LABELING OF
BAROSTIM
Source text for Eikon: ID:nGNX4Wvqvl
Further company coverage: CVRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CVRx
See all newsBrief: CVRx Announces Humana Medicare Advantage Coverage Policy For Barostim Therapy
CVRx's Q1 revenue rises 20%, beats expectations
Brief: CVRx Q1 Revenue USD 14.769 Million Vs. IBES Estimate USD 14.5 Million
CVRx preliminary Q1 revenue rises 20%, gross margin improves
CVRx Q4 revenue rises 4%, beats expectations